Story thread · 2 reports / 2 sources

First New Drug Approved for Idiopathic Nephrotic Syndrome in 70 Years

medpagetoday.com · 3hShare

(MedPage Today) -- The FDA expanded the indications for the B-cell depleter obinutuzumab (Gazyva) to include idiopathic nephrotic syndrome, the agency announced on Friday, the first new option for the rare kidney disease in more than half a century...

First report: Genentech's Gazyva gains indication for idiopathic nephrotic syndrome — seekingalpha.com, 3d